nach oben

Erschienen in:

06.01.2023 | Review Article

Acute, chronic, and post-mortem toxicity: a review focused on three different classes of new psychoactive substances

verfasst von: Caio H. P. Rodrigues, Lívia S. Mariotto, Jade S. Castro, Paulo H. Peruquetti, Newton C. Silva-Junior, Aline T. Bruni

Erschienen in: Forensic Toxicology | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

New psychoactive substances (NPS) are not controlled under the Single Convention on Narcotic Drugs of 1961 or the 1971 Convention, but they may pose a public health threat. Knowledge of the main properties and toxicological effects of these substances is lacking. According to the current Drugs Law (Law n. 11.343/2006), the Brazilian Surveillance Agency issues directives for forbidden substances in Brazil, and structural classes of synthetic cannabinoids, cathinones, and phenylethylamines are considered illicit drugs. Considering that data on these controlled substances are scattered, the main objective of this work was to collect and organize data to generate relevant information on the toxicological properties of NPS.

Methods

We carried out a literature review collecting information on the acute, chronic, and post-mortem toxicity of these classes of NSP. We searched info in five scientific databases considering works from 2017 to 2021 and performed a statistical evaluation of the data.

Results

Results have shown a general lack of studies in this field given that many NPS have not had their toxicity evaluated. We observed a significant difference in the volume of data concerning acute and chronic/post-mortem toxicity. Moreover, studies on the adverse effects of polydrug use are scarce.

Conclusions

More in-depth information about the main threats involving NPS use are needed.

Nur mit Berechtigung zugänglich

UNODC (2022). World Drug Report - Executive Summary: Policy Implications. https://www.unodc.org/unodc/en/data-and-analysis/wdr-2022_booklet-1.html. Accessed 4 Dec 2022

UNODC (2019). Current NPS Threats Volume I. https://www.unodc.org/documents/scientific/Current_NPS_Threats_Volume_I.pdf. Accessed 4 Dec 2022

UNODC (2020). Current NPS Threats, Volume III. https://www.unodc.org/documents/scientific/Current_NPS_Threats_Vol.3.pdf. Accessed 4 Dec 2022

Oga S, de Camargo MMA, de Batistuzzo JAO (2021) Fundamentos de toxicologia, 5th edn. Grupo Atheneu, São Paulo

Gupta PK (2016) Principles and basic concepts of toxicokinetics. In: Gupta PK (ed) Fundamentals of toxicology, 1st edn. Elsevier, Bareilly, pp 87–107. https://doi.org/10.1016/B978-0-12-805426-0.00035-4 CrossRef

Lehman-McKeeman LD (2015) Absorption, distribution, and excretion of toxicants. In: Klaassen CD, Watkins-III JB (eds) Casarett & Doull’s essentials of toxicology, 3rd edn. McGraw-Hill Education, New York

SWGTOX (2013) Scientific working group for forensic toxicology (SWGTOX) standard practices for method validation in forensic toxicology. J Anal Toxicol 37:452–474. https://doi.org/10.1093/jat/bkt054 CrossRef

Penders J, Verstraete A (2006) Laboratory guidelines and standards in clinical and forensic toxicology. Accred Qual Assur 11:284–290. https://doi.org/10.1007/s00769-006-0131-y CrossRef

Elliott SP, Stephen DWS, Paterson S (2018) The United Kingdom and Ireland association of forensic toxicologist’s forensic toxicology laboratory guidelines (2018). Sci Justice 58:335–345. https://doi.org/10.1016/j.scijus.2018.05.004 CrossRefPubMed

10.

Maxwell L (2020) Absorption, distribution, and excretion in complex organisms. In: Pope CN, Liu J (eds) An introduction to interdisciplinary toxicology, 1st edn. Academic Press, San Diego, pp 17–29. https://doi.org/10.1016/B978-0-12-813602-7.00002-8 CrossRef

11.

Hafeez R, Nadeem Z, Iftikhar S (2019) Environmental toxicology. In: Iftikhar S (ed) Trends of environmental forensics in Pakistan, 1st edn. Academic Press, Rawalpindi, pp 1–21. https://doi.org/10.1016/C2018-0-04671-X CrossRef

12.

Gerba CP (2019) Environmental toxicology. In: Brusseau ML, Pepper IL, Gerba CP (eds) Environmental and pollution science, 3rd edn. Elsevier, San Diego, pp 511–540. https://doi.org/10.1016/C2017-0-00480-9 CrossRef

13.

Subramanian MA (2010) Absorption of toxicants. In: Subramanian MA (ed) Toxicology: principles and methods, 1st edn. MJP Publishers, Chennai, p 350

14.

Strolin Benedetti M, Whomsley R, Baltes EL (2005) Differences in absorption, distribution, metabolism and excretion of xenobiotics between the pediatric and adult populations. Expert Opin Drug Metab Toxicol 1:447–471. https://doi.org/10.1517/17425255.1.3.447 CrossRefPubMed

15.

Baynes RE, Hodgson E (2004) Absorption and distribution of toxicants. In: Hodgson E (ed) A textbook of modern toxicology, 3rd edn. Wiley, Hoboken, pp 75–110. https://doi.org/10.1002/0471646776 CrossRef

16.

Rajpoot K, Tekade M, Sharma MC et al (2022) Principles and concepts in toxicokinetic. Pharmacokinetics and toxicokinetic considerations. Elsevier, San Diego, pp 1–26. https://doi.org/10.1016/C2021-0-01019-1 CrossRef

17.

Fleck C, Bräunlich H (1990). Factors determining the relationship between renal and hepatic excretion of xenobiotics. Arzneimittelforschung 40:942–6. https://pubmed.ncbi.nlm.nih.gov/2242089/. Accessed 4 Dec 2022

18.

Pritchard JB, Bend JR (1984) Mechanisms controlling the renal excretion of xenobiotics in fish: effects of chemical structure. Drug Metab Rev 15:655–671. https://doi.org/10.3109/03602538409041075 CrossRefPubMed

19.

Nordberg GF, Fowler BA (2019) Biomonitoring, mode of action (MOA), target dose, and adverse outcome pathways (AOPs). In: Nordberg F, Fowler BA (eds) Risk assessment for human metal exposures, 1st edn. Elsevier, San Diego, pp 75–98. https://doi.org/10.1016/C2015-0-01335-1 CrossRef

20.

Ashauer R, Escher BI (2010) Advantages of toxicokinetic and toxicodynamic modelling in aquatic ecotoxicology and risk assessment. J Environ Monit 12:2056. https://doi.org/10.1039/c0em00234h CrossRefPubMed

21.

Walum E (1998) Acute oral toxicity. Environ Health Perspect 106:497–503. https://doi.org/10.1289/ehp.98106497 CrossRefPubMedPubMedCentral

22.

Rispin A, Farrar D, Margosches E et al (2002) Alternative methods for the median Lethal Dose (LD50) Test: the up-and-down procedure for acute oral toxicity. ILAR J 43:233–243. https://doi.org/10.1093/ilar.43.4.233 CrossRefPubMed

23.

Shapiro-Ilan DI, Fuxa JR, Lacey LA et al (2005) Definitions of pathogenicity and virulence in invertebrate pathology. J Invertebr Pathol 88:1–7. https://doi.org/10.1016/j.jip.2004.10.003 CrossRefPubMed

24.

Wang J, Stresser DM (2022) Principles of pharmacodynamics and toxicodynamics. In: Haschek WM, Rousseaux CG, Wallig MA, Bolon B (eds) Haschek and Rousseaux’s handbook of toxicologic pathology, 4th edn. Elsevier, San Diego, pp 101–112. https://doi.org/10.1016/C2010-1-67850-9 CrossRef

25.

Omiecinski CJ, van den Heuvel JP, Perdew GH, Peters JM (2011) Xenobiotic metabolism, disposition, and regulation by receptors: from biochemical phenomenon to predictors of major toxicities. Toxicol Sci 120:S49–S75. https://doi.org/10.1093/toxsci/kfq338 CrossRefPubMed

26.

Hakkola J, Bernasconi C, Coecke S et al (2018) Cytochrome P450 induction and xeno-sensing receptors pregnane x receptor, constitutive androstane receptor, aryl hydrocarbon receptor and peroxisome proliferator-activated receptor α at the crossroads of toxicokinetics and toxicodynamics. Basic Clin Pharmacol Toxicol 123:42–50. https://doi.org/10.1111/bcpt.13004 CrossRefPubMed

27.

Dybing E, Søderlund EJ (1999) Situations with enhanced chemical risks due to toxicokinetic and toxicodynamic factors. Regulat Toxicol Pharmacol 30:S27–S30. https://doi.org/10.1006/rtph.1999.1322 CrossRef

28.

Richardson RJ (2020) Toxicant interactions with macromolecular targets. In: Pope CN, Liu J (eds) An introduction to interdisciplinary toxicology, 1st edn. Elsevier, San Diego, pp 45–57. https://doi.org/10.1016/C2016-0-04892-1 CrossRef

29.

Gehring R, van der Merwe D (2014) Toxicokinetic-toxicodynamic modeling. In: Gupta RC (ed) Biomarkers in toxicology, 1st edn. Elsevier, San Diego, pp 149–153. https://doi.org/10.1016/C2012-0-01373-7 CrossRef

30.

Booth WC, Colomb GG, Williams JM (2005) A arte da pesquisa, 2 ^a Edição. Martins Fontes—Selo Martins, São Paulo

31.

Gusenbauer M (2019) Google Scholar to overshadow them all? Comparing the sizes of 12 academic search engines and bibliographic databases. Scientometrics 118:177–214. https://doi.org/10.1007/s11192-018-2958-5 CrossRef

32.

Barbosa DJ, Gomes MP, Gomes AMT, de Souza FBA (2020) Relação entre o consumo de drogas psicoativas e COVID-19. JMPHC- J Manag Prim Health Care 12:1–9. https://doi.org/10.14295/jmphc.v12.1000 CrossRef

33.

Aldubayyan AA, Castrignanò E, Elliott S, Abbate V (2021) Stability of synthetic cathinones in clinical and forensic toxicological analysis—where are we now? Drug Test Anal 13:44–68. https://doi.org/10.1002/dta.2990 CrossRefPubMed

34.

Li X, Cundy AB, Chen W, Lyu S (2021) Systematic and bibliographic review of sustainability indicators for contaminated site remediation: comparison between China and western nations. Environ Res 200:111490. https://doi.org/10.1016/j.envres.2021.111490 CrossRefPubMed

35.

Heal DJ, Smith SL, Gosden J, Nutt DJ (2013) Amphetamine, past and present—a pharmacological and clinical perspective. J Psychopharmacol 27:479–496. https://doi.org/10.1177/0269881113482532 CrossRefPubMedPubMedCentral

36.

Brensilver M, Heinzerling KG, Shoptaw S (2013) Pharmacotherapy of amphetamine-type stimulant dependence: an update. Drug Alcohol Rev 32:449–460. https://doi.org/10.1111/dar.12048 CrossRefPubMedPubMedCentral

37.

Degenhardt L, Whiteford HA, Ferrari AJ et al (2013) Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of disease study 2010. Lancet 382:1564–1574. https://doi.org/10.1016/S0140-6736(13)61530-5 CrossRefPubMed

38.

Courtney KE, Ray LA (2014) Methamphetamine: an update on epidemiology, pharmacology, clinical phenomenology and treatment literature. Drug Alcohol Depend 143:11–21. https://doi.org/10.1016/j.drugalcdep.2014.08.003 CrossRefPubMed

39.

Abbott R, Smith DE (2015) The new designer drug wave: a clinical, toxicological, and legal analysis. J Psychoactive Drugs 47:368–371. https://doi.org/10.1080/02791072.2015.1094591 CrossRefPubMed

40.

de Felice LJ, Glennon RA, Negus SS (2014) Synthetic cathinones: chemical phylogeny, physiology, and neuropharmacology. Life Sci 97:20–26. https://doi.org/10.1016/j.lfs.2013.10.029 CrossRefPubMed

41.

Sitte HH, Freissmuth M (2015) Amphetamines, new psychoactive drugs and the monoamine transporter cycle. Trends Pharmacol Sci 36:41–50. https://doi.org/10.1016/j.tips.2014.11.006 CrossRefPubMed

42.

Miotto K, Striebel J, Cho AK, Wang C (2013) Clinical and pharmacological aspects of bath salt use: a review of the literature and case reports. Drug Alcohol Depend 132:1–12. https://doi.org/10.1016/j.drugalcdep.2013.06.016 CrossRefPubMed

43.

Tran MTN, Luong QH, le Minh G et al (2021) Psychosocial interventions for amphetamine type stimulant use disorder: an overview of systematic reviews. Front Psychiatry 12:1–14. https://doi.org/10.3389/fpsyt.2021.512076 CrossRef

44.

Luethi D, Liechti ME (2020) Designer drugs: mechanism of action and adverse effects. Arch Toxicol 94:1085–1133. https://doi.org/10.1007/s00204-020-02693-7 CrossRefPubMedPubMedCentral

45.

Batisse A, Eiden C, Peyriere H, Djezzar S (2020) Use of new psychoactive substances to mimic prescription drugs: the trend in France. Neurotoxicology 79:20–24. https://doi.org/10.1016/j.neuro.2020.03.015 CrossRefPubMed

46.

Zapata F, Matey JM, Montalvo G, García-Ruiz C (2021) Chemical classification of new psychoactive substances (NPS). Microchem J 163:105877. https://doi.org/10.1016/j.microc.2020.105877 CrossRef

47.

Feng L-Y, Battulga A, Han E et al (2017) New psychoactive substances of natural origin: a brief review. J Food Drug Anal 25:461–471. https://doi.org/10.1016/j.jfda.2017.04.001 CrossRefPubMedPubMedCentral

48.

Soares J, Costa VM, de Bastos ML et al (2021) An updated review on synthetic cathinones. Arch Toxicol 95:2895–2940. https://doi.org/10.1007/s00204-021-03083-3 CrossRefPubMed

49.

Khan I (1979) Convention on psychotropic substances, 1971. Prog Neuropsychopharmacol 3:11–14. https://doi.org/10.1016/0364-7722(79)90064-X CrossRefPubMed

50.

Bruni A, Rodrigues C, dos Santos C et al (2021) Analytical challenges for identification of new psychoactive substances: a literature-based study for seized drugs. Braz J Anal Chem 9:52–78. https://doi.org/10.30744/brjac.2179-3425.RV-41-2021 CrossRef

51.

Jîtcă G, Ősz BE, Tero-Vescan A, Vari CE (2021) Psychoactive drugs—from chemical structure to oxidative stress related to dopaminergic neurotransmission. A review. Antioxidants 10:381. https://doi.org/10.3390/antiox10030381 CrossRefPubMedPubMedCentral

52.

Layne K, Dargan PI, Wood DM (2022) Synthetic cathinones. In: Dargan P, Wood D (eds) Novel psychoactive substances, 2nd edn. Elsevier, Oxford, pp 333–380. https://doi.org/10.1016/C2018-0-04223-1 CrossRef

53.

Silva B, Soares J, Rocha-Pereira C et al (2022) Khat, a cultural chewing drug: a toxicokinetic and toxicodynamic summary. Toxins (Basel) 14:71. https://doi.org/10.3390/toxins14020071 CrossRefPubMed

54.

Kurcevič E, Lines R (2020) New psychoactive substances in Eurasia: a qualitative study of people who use drugs and harm reduction services in six countries. Harm Reduct J 17:1–13. https://doi.org/10.1186/s12954-020-00448-2 CrossRef

55.

Ferrari Júnior E, dos Santos JBA, Caldas ED (2021) Drugs, pesticides and metabolites in forensic post-mortem blood samples. Med Sci Law 61:97–104. https://doi.org/10.1177/0025802420965006 CrossRefPubMed

56.

Karila L, Benyamina A (2018) The effects and risks associated with synthetic cathinones use in humans. In: Zawilska JB (ed) Synthetic cathinones: novel addictive and stimulatory psychoactive substances, 1st edn. Springer Cham, Łódź, pp 191–202. https://doi.org/10.1007/978-3-319-78707-7_10 CrossRef

57.

Martins D, Valente H, Pires C (2015) CHECK!NG: a última fronteira para a Redução de Riscos em contextos festivos. Saúde e Sociedade 24:646–660. https://doi.org/10.1590/S0104-12902015000200020 CrossRef

58.

Pieprzyca E, Skowronek R, Nižnanský Ľ, Czekaj P (2020) Synthetic cathinones—from natural plant stimulant to new drug of abuse. Eur J Pharmacol 875:173012. https://doi.org/10.1016/j.ejphar.2020.173012 CrossRefPubMed

59.

Hudson M, Stuchinskaya T, Ramma S et al (2019) Drug screening using the sweat of a fingerprint: lateral flow detection of Δ9-tetrahydrocannabinol, cocaine, opiates and amphetamine. J Anal Toxicol 43:88–95. https://doi.org/10.1093/jat/bky068 CrossRefPubMed

60.

Dragan A-M, Parrilla M, Feier B et al (2021) Analytical techniques for the detection of amphetamine-type substances in different matrices: a comprehensive review. Trends Anal Chem 145:116447. https://doi.org/10.1016/j.trac.2021.116447 CrossRef

61.

Shafi A, Berry AJ, Sumnall H et al (2020) New psychoactive substances: a review and updates. Ther Adv Psychopharmacol 10:204512532096719. https://doi.org/10.1177/2045125320967197 CrossRef

62.

Prosser JM, Nelson LS (2012) The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol 8:33–42. https://doi.org/10.1007/s13181-011-0193-z CrossRefPubMed

63.

Jarończyk M, Walory J (2022) Novel molecular targets of antidepressants. Molecules 27:533. https://doi.org/10.3390/molecules27020533 CrossRefPubMedPubMedCentral

64.

Leyrer-Jackson JM, Nagy EK, Olive MF (2019) Cognitive deficits and neurotoxicity induced by synthetic cathinones: is there a role for neuroinflammation? Psychopharmacology 236:1079–1095. https://doi.org/10.1007/s00213-018-5067-5 CrossRefPubMed

65.

Kalix P (1992) Cathinone, a natural amphetamine. Pharmacol Toxicol 70:77–86. https://doi.org/10.1111/j.1600-0773.1992.tb00434.x CrossRefPubMed

66.

Kevil CG, Goeders NE, Woolard MD et al (2019) Methamphetamine use and cardiovascular disease. Arterioscler Thromb Vasc Biol 39:1739–1746. https://doi.org/10.1161/ATVBAHA.119.312461 CrossRefPubMedPubMedCentral

67.

Lapoint J, Welker KL (2022) Synthetic amphetamine derivatives, benzofurans, and benzodifurans. In: Dargan P, Wood D (eds) Novel psychoactive substances, 2nd edn. Elsevier, Oxford, pp 247–278. https://doi.org/10.1016/B978-0-12-818788-3.00007-3 CrossRef

68.

Carboni E, Spielewoy C, Vacca C et al (2001) Cocaine and Amphetamine increase extracellular dopamine in the nucleus accumbens of mice lacking the dopamine transporter gene. J Neurosci 21:RC141. https://doi.org/10.1523/JNEUROSCI.21-09-j0001.2001 CrossRefPubMedPubMedCentral

69.

Standaert DG, Walsh RR (2011) Pharmacology of dopaminergic neurotransmission. In: Golan DE, Tashjian AH, Armstrong EJ, Armstrong AW (eds) Principles of pharmacology: the pathophysiologic basis of drug therapy, 3rd edn. Lippincott Williams & Wilkins, Philadelphia

70.

Sahai MA, Opacka-Juffry J (2021) Molecular mechanisms of action of stimulant novel psychoactive substances that target the high-affinity transporter for dopamine. Neuronal Signal. https://doi.org/10.1042/NS20210006 CrossRefPubMedPubMedCentral

71.

Liechti ME (2015) Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signalling. Swiss Med Wkly 145:1–12. https://doi.org/10.4414/smw.2015.14043 CrossRef

72.

Lopez-Rodriguez AB, Viveros M-P (2019) Bath salts and polyconsumption: in search of drug-drug interactions. Psychopharmacology 236:1001–1014. https://doi.org/10.1007/s00213-019-05213-3 CrossRefPubMed

73.

Dominic P, Ahmad J, Awwab H et al (2022) Stimulant drugs of abuse and cardiac arrhythmias. Circ Arrhythm Electrophysiol 15:71–83. https://doi.org/10.1161/CIRCEP.121.010273 CrossRef

74.

Angoa-Pérez M, Zagorac B, Winters AD et al (2020) Differential effects of synthetic psychoactive cathinones and amphetamine stimulants on the gut microbiome in mice. PLoS ONE 15:e0227774. https://doi.org/10.1371/journal.pone.0227774 CrossRefPubMedPubMedCentral

75.

Zordok M, Anis K, Fernandez LS, Singh H (2020) Amphetamine-induced disseminated intravascular coagulation: a case report. Chest 158:A989. https://doi.org/10.1016/j.chest.2020.08.920 CrossRef

76.

Grafinger KE, Liechti ME, Liakoni E (2020) Clinical value of analytical testing in patients presenting with new psychoactive substances intoxication. Br J Clin Pharmacol 86:429–436 CrossRefPubMed

77.

Rudin D, Liechti ME, Luethi D (2021) Molecular and clinical aspects of potential neurotoxicity induced by new psychoactive stimulants and psychedelics. Exp Neurol 343:113778. https://doi.org/10.1016/j.expneurol.2021.113778 CrossRefPubMed

78.

Majchrzak M, Celiński R, Kuś P et al (2018) The newest cathinone derivatives as designer drugs: an analytical and toxicological review. Forensic Toxicol 36:33–50. https://doi.org/10.1007/s11419-017-0385-6 CrossRefPubMed

79.

Mead J, Parrott A (2020) Mephedrone and MDMA: a comparative review. Brain Res 1735:146740. https://doi.org/10.1016/j.brainres.2020.146740 CrossRefPubMed

80.

Angoa-Pérez M, Kane MJ, Francescutti DM et al (2012) Mephedrone, an abused psychoactive component of ‘bath salts’ and methamphetamine congener, does not cause neurotoxicity to dopamine nerve endings of the striatum. J Neurochem. https://doi.org/10.1111/j.1471-4159.2011.07632.x CrossRefPubMedPubMedCentral

81.

German CL, Fleckenstein AE, Hanson GR (2014) Bath salts and synthetic cathinones: an emerging designer drug phenomenon. Life Sci 97:2–8. https://doi.org/10.1016/j.lfs.2013.07.023 CrossRefPubMed

82.

Paul A (2021) Adrenergic agonists. In: Paul A, Anandabaskar N, Mathaiyan J, Raj GM (eds) Introduction to basics of pharmacology and toxicology. Springer, Singapore, pp 41–53. https://doi.org/10.1007/978-981-33-6009-9_3 CrossRef

83.

Abdulrahim D, Bowden-Jones O (2022) Addiction and treatment of novel psychoactive substance dependence. In: Dargan P, Wood D (eds) Novel psychoactive substances, 2nd edn. Elsevier, Oxford, pp 203–222 CrossRef

84.

Schmutte T, Costa M, Hammer P, Davidson L (2021) Comparisons between suicide in persons with serious mental illness, other mental disorders, or no known mental illness: results from 37 U.S. States, 2003–2017. Schizophr Res 228:74–82. https://doi.org/10.1016/j.schres.2020.11.058 CrossRefPubMedPubMedCentral

85.

dos Moreira AMS, de Oliveira HL, Allochio Filho JF et al (2019) NBOMe compounds: an overview about analytical methodologies aiming their determination in biological matrices. Trends Anal Chem 114:260–277. https://doi.org/10.1016/j.trac.2019.02.034 CrossRef

86.

Yoshida K, Saka K, Shintani-Ishida K et al (2015) A case of fatal intoxication due to the new designer drug 25B-NBOMe. Forensic Toxicol 33:396–401. https://doi.org/10.1007/s11419-015-0276-7 CrossRef

87.

Chung H, Lee J, Kim E (2016) Trends of novel psychoactive substances (NPSs) and their fatal cases. Forensic Toxicol 34:1–11. https://doi.org/10.1007/s11419-015-0286-5 CrossRef

88.

Lawn W, Barratt M, Williams M et al (2014) The NBOMe hallucinogenic drug series: patterns of use, characteristics of users and self-reported effects in a large international sample. J Psychopharmacol 28:780–788. https://doi.org/10.1177/0269881114523866 CrossRefPubMed

89.

Wood DM, Sedefov R, Cunningham A, Dargan PI (2015) Prevalence of use and acute toxicity associated with the use of NBOMe drugs. Clin Toxicol 53:85–92. https://doi.org/10.3109/15563650.2015.1004179 CrossRef

90.

Suzuki J, Dekker MA, Valenti ES et al (2015) Toxicities associated with NBOMe ingestion—a novel class of potent hallucinogens: a review of the literature. Psychosomatics 56:129–139. https://doi.org/10.1016/j.psym.2014.11.002 CrossRefPubMed

91.

Brandt SD, Elliott SP, Kavanagh PV et al (2015) Analytical characterization of bioactive N-benzyl-substituted phenethylamines and 5-methoxytryptamines. Rapid Commun Mass Spectrom 29:573–584. https://doi.org/10.1002/rcm.7134 CrossRefPubMed

92.

Tang MHY, Ching CK, Tsui MSH et al (2014) Two cases of severe intoxication associated with analytically confirmed use of the novel psychoactive substances 25B-NBOMe and 25C-NBOMe. Clin Toxicol 52:561–565. https://doi.org/10.3109/15563650.2014.909932 CrossRef

93.

Morini L, Bernini M, Vezzoli S et al (2017) Death after 25C-NBOMe and 25H-NBOMe consumption. Forensic Sci Int 279:e1–e6. https://doi.org/10.1016/j.forsciint.2017.08.028 CrossRefPubMed

94.

Richter LHJ, Menges J, Wagmann L et al (2020) In vitro toxicokinetics and analytical toxicology of three novel NBOMe derivatives: phase I and II metabolism, plasma protein binding, and detectability in standard urine screening approaches studied by means of hyphenated mass spectrometry. Forensic Toxicol 38:141–159. https://doi.org/10.1007/s11419-019-00498-7 CrossRef

95.

de Barros WA, Queiroz MP, da SilvaNeto L et al (2021) Synthesis of 25X-BOMes and 25X-NBOHs (X = H, I, Br) for pharmacological studies and as reference standards for forensic purposes. Tetrahedron Lett 66:152804. https://doi.org/10.1016/j.tetlet.2020.152804 CrossRef

96.

UNODC (2013). The International Drug Control Conventions. United Nations, New York. https://www.unodc.org/documents/commissions/CND/Int_Drug_Control_Conventions/Ebook/The_International_Drug_Control_Conventions_E.pdf. Accessed 4 Dec 2022

97.

International Narcotics Control Board (2021). Green List. In: List of Psychotropic Substances Under International Control. https://www.incb.org/documents/Psychotropics/forms/greenlist/2021/Green_list_ENG_V21.pdf. Accessed 4 Dec 2022

98.

UNODC (2015). Report of the Commission on Narcotic Drugs on the Fifty-eighth Session (5 December 2014 and 9–17 March 2015). https://documents-dds-ny.un.org/doc/UNDOC/GEN/V15/021/78/PDF/V1502178.pdf?OpenElement. Accessed 4 Dec 2022

99.

Potts AJ, Thomas SHL, Hill SL (2022) Pharmacology and toxicology of N-Benzyl-phenylethylamines (25X-NBOMe) hallucinogens. In: Dargan P, Wood D (eds) Novel Psychoactive Substances, 2nd edn. Elsevier, Oxford, pp 279–300. https://doi.org/10.1016/B978-0-12-818788-3.00008-5 CrossRef

100.

Zawilska JB, Kacela M, Adamowicz P (2020) NBOMes–highly potent and toxic alternatives of LSD. Front Neurosci. https://doi.org/10.3389/fnins.2020.00078 CrossRefPubMedPubMedCentral

101.

Šuláková A, Nykodemová J, Palivec P et al (2021) 25CN-NBOMe metabolites in rat urine, human liver microsomes and C. elegans—structure determination and synthesis of the most abundant metabolites. Metabolites 11:212. https://doi.org/10.3390/metabo11040212 CrossRefPubMedPubMedCentral

102.

Caspar AT, Meyer MR, Maurer HH (2018) Human cytochrome P450 kinetic studies on six N -2-methoxybenzyl (NBOMe)-derived new psychoactive substances using the substrate depletion approach. Toxicol Lett 285:1–8. https://doi.org/10.1016/j.toxlet.2017.12.017 CrossRefPubMed

103.

Brooks C, Gibson AR, Miell J (2017) Acute toxicity related to 25G-NBOMe use: an internet high. J Acute Med 7:40–43. https://doi.org/10.6705/j.jacme.2017.0701.007 CrossRefPubMedPubMedCentral

104.

Álvarez-Alarcón N, Osorio-Méndez JJ, Ayala-Fajardo A et al (2021) Zebrafish and Artemia salina in vivo evaluation of the recreational 25C-NBOMe drug demonstrates its high toxicity. Toxicol Rep 8:315–323. https://doi.org/10.1016/j.toxrep.2021.01.010 CrossRefPubMedPubMedCentral

105.

Herian M, Skawski M, Wojtas A et al (2021) Tolerance to neurochemical and behavioral effects of the hallucinogen 25I-NBOMe. Psychopharmacology 238:2349–2364. https://doi.org/10.1007/s00213-021-05860-5 CrossRefPubMedPubMedCentral

106.

Herian M, Wojtas A, Kamińska K et al (2019) Hallucinogen-like action of the novel designer drug 25I-NBOMe and its effect on cortical neurotransmitters in rats. Neurotox Res 36:91–100. https://doi.org/10.1007/s12640-019-00033-x CrossRefPubMedPubMedCentral

107.

Seo J-Y, Hur K-H, Ko Y-H et al (2019) A novel designer drug, 25N-NBOMe, exhibits abuse potential via the dopaminergic system in rodents. Brain Res Bull 152:19–26. https://doi.org/10.1016/j.brainresbull.2019.07.002 CrossRefPubMed

108.

Madsen GR, Petersen TS, Dalhoff KP (2017) NBOMe hallucinogenic drug exposures reported to the Danish Poison information centre. Dan Med J 64:A5386 PubMed

109.

Waldman W, Kała M, Lechowicz W et al (2018) Severe clinical toxicity caused by 25I-NBOMe confirmed analytically using LC-MS-MS method. Acta Biochim Pol 65:567–571. https://doi.org/10.18388/abp.2018_2627 CrossRefPubMed

110.

Schetz D, Schetz A, Kocić I (2022) A retrospective analysis of the “Neverending Trip” after administration of a potent full agonist of 5-HT2A receptor—25I-NBOMe. Biomed Pharmacother 146:112295. https://doi.org/10.1016/j.biopha.2021.112295 CrossRefPubMed

111.

United Nations Office on Drugs and Crime - UNODC (2013). World Drug Report 2013, 1st ed. United Nations publication, Sales No. E.13.XI.6, Vienna

112.

Tavares IS, Yonamine M (2018) Novas substâncias psicoativas: canabinóides sintéticos, derivados da fenetilamina e derivados da triptamina. In: Dorta DJ, Yonamine M, da Costa JL, de Martinis BS (eds) Toxicologia Forense, 1st edn. Blucher, São Paulo, pp 237–253

113.

Courts J, Maskill V, Gray A, Glue P (2016) Signs and symptoms associated with synthetic cannabinoid toxicity: systematic review. Austral Psychiat 24:598–601. https://doi.org/10.1177/1039856216663733 CrossRef

114.

Harris CR, Brown A (2013) Synthetic cannabinoid intoxication: a case series and review. J Emerg Med 44:360–366. https://doi.org/10.1016/j.jemermed.2012.07.061 CrossRefPubMed

115.

Wiley JL, Marusich JA, Thomas BF (2016) Combination chemistry: structure-activity relationships of novel psychoactive cannabinoids. In: Baumann MH, Glennon RA, Wiley JL (eds) Neuropharmacology of new psychoactive substances (NPS). Current topics in behavioral neurosciences, 1st edn. Springer Cham, San Diego, pp 231–248. https://doi.org/10.1007/7854_2016_17 CrossRef

116.

White CM (2017) The pharmacologic and clinical effects of illicit synthetic cannabinoids. J Clin Pharmacol 57:297–304. https://doi.org/10.1002/jcph.827 CrossRefPubMed

117.

Forrester M, Kleinschmidt K, Schwarz E, Young A (2012) Synthetic cannabinoid and marijuana exposures reported to poison centers. Hum Exp Toxicol 31:1006–1011. https://doi.org/10.1177/0960327111421945 CrossRefPubMed

118.

Yip L, Dart RC (2014) Is there something more about synthetic cannabinoids? Forensic Toxicol 32:340–341. https://doi.org/10.1007/s11419-013-0224-3 CrossRef

119.

UNODC (2021). World Drug Report - Executive Summary: Policy Implications, https://www.unodc.org/res/wdr2021/field/WDR21_Booklet_1.pdf. Accessed 4 Dec 2022

120.

Ayonrinde OA (2020) Cannabis and psychosis: revisiting a nineteenth century study of ‘Indian Hemp and Insanity’ in Colonial British India. Psychol Med 50:1164–1172. https://doi.org/10.1017/S0033291719001077 CrossRefPubMed

121.

Crocq M-A (2020) History of cannabis and the endocannabinoid system. Dialogues Clin Neurosci 22:223–228. https://doi.org/10.31887/DCNS.2020.22.3/mcrocq CrossRefPubMedPubMedCentral

122.

Metternich S, Fischmann S, Münster-Müller S et al (2020) Discrimination of synthetic cannabinoids in herbal matrices and of cathinone derivatives by portable and laboratory-based Raman spectroscopy. Forensic Chem 19:100241. https://doi.org/10.1016/j.forc.2020.100241 CrossRef

123.

Christian DR Jr (2003) Forensic investigation of clandestine laboratories. 1st edn. CRC Press, Boca Raton. https://doi.org/10.1201/9780203484548 CrossRef

124.

United Nations Office on Drugs and Crime - UNODC (2020). Cross-cutting issues: evolving trends and new challenges. United Nations publication, Sales No. E.20.XI.6, Vienna

125.

Alipour A, Patel PB, Shabbir Z, Gabrielson S (2019) Review of the many faces of synthetic cannabinoid toxicities. Mental Health Clinician 9:93–99. https://doi.org/10.9740/mhc.2019.03.093 CrossRefPubMedPubMedCentral

126.

Khanolkar AD, Palmer SL, Makriyannis A (2000) Molecular probes for the cannabinoid receptors. Chem Phys Lipids 108:37–52. https://doi.org/10.1016/S0009-3084(00)00186-9 CrossRefPubMed

127.

Castaneto MS, Wohlfarth A, Desrosiers NA et al (2015) Synthetic cannabinoids pharmacokinetics and detection methods in biological matrices. Drug Metab Rev 47:124–174. https://doi.org/10.3109/03602532.2015.1029635 CrossRefPubMed

128.

Gonçalves J, Rosado T, Soares S et al (2019) Cannabis and its secondary metabolites: their use as therapeutic drugs, toxicological aspects, and analytical determination. Medicines 6:31. https://doi.org/10.3390/medicines6010031 CrossRefPubMedPubMedCentral

129.

Silvado C (2008) Farmacogenética e antiepilépticos (farmacologia das drogas antiepilépticas: da teoria à prática). J Epilep Clin Neurophysiol 14:51–56. https://doi.org/10.1590/S1676-26492008000600009 CrossRef

130.

Alsherbiny M, Li C (2018) Medicinal cannabis—potential drug interactions. Medicines 6:3. https://doi.org/10.3390/medicines6010003 CrossRefPubMedPubMedCentral

131.

Sharma P, Murthy P, Bharath MMS (2012) Chemistry, metabolism, and toxicology of cannabis: clinical implications. Iran J Psychiat 7:149–156

132.

Yonamine M (2004) A saliva como espécime biológico para monitorar o uso de álcool, anfetamina, metanfetamina, cocaína e maconha por motoristas profissionais. Universidade de São Paulo, São Paulo. https://doi.org/10.11606/T.9.2004.tde-03072008-093347 CrossRef

133.

Wintermeyer A, Möller I, Thevis M et al (2010) In vitro phase I metabolism of the synthetic cannabimimetic JWH-018. Anal Bioanal Chem 398:2141–2153. https://doi.org/10.1007/s00216-010-4171-0 CrossRefPubMed

134.

Howlett AC, Abood ME (2017) CB1 and CB2 receptor pharmacology. Adv Pharmacol 80:169–206. https://doi.org/10.1016/bs.apha.2017.03.007 CrossRefPubMedPubMedCentral

135.

Lobato-Freitas C, Brito-da-Costa AM, Dinis-Oliveira RJ et al (2021) Overview of synthetic cannabinoids ADB-FUBINACA and AMB-FUBINACA: clinical, analytical, and forensic implications. Pharmaceuticals 14:186. https://doi.org/10.3390/ph14030186 CrossRefPubMedPubMedCentral

136.

Cottencin O, Rolland B, Karila L (2013) New designer drugs (synthetic cannabinoids and synthetic cathinones): review of literature. Curr Pharm Des. https://doi.org/10.2174/13816128113199990622 CrossRef

137.

Chung EY, Cha HJ, Min HK, Yun J (2021) Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists. Arch Pharm Res 44:402–413. https://doi.org/10.1007/s12272-021-01326-6 CrossRefPubMed

138.

Malaca S, Busardò FP, Nittari G et al (2022) Fourth generation of synthetic cannabinoid receptor agonists: a review on the latest insights. Curr Pharm Des 28:2603–2617. https://doi.org/10.2174/1381612827666211115170521 CrossRefPubMed

139.

Simon G, Tóth D, Heckmann V et al (2022) Lethal case of myocardial ischemia following overdose of the synthetic cannabinoid ADB-FUBINACA. Leg Med 54:102004. https://doi.org/10.1016/j.legalmed.2021.102004 CrossRef

140.

Pascoe MJ, Radley S, Simmons HTD, Measham F (2022) The cathinone hydra: increased cathinone and caffeine adulteration in the English MDMA market after Brexit and COVID-19 lockdowns. Drug Sci Policy Law 8:205032452210992. https://doi.org/10.1177/20503245221099209 CrossRef

141.

West H, Fitzgerald J, Hopkins K et al (2021) Early warning system for illicit drug use at large public events: trace residue analysis of discarded drug packaging samples. J Am Soc Mass Spectrom 32:2604–2614. https://doi.org/10.1021/jasms.1c00232 CrossRefPubMed

142.

EMCDDA (2021) European drug report 2021: trends and developments. https://doi.org/10.2810/18539

143.

EMCDDA (2020) European drug report 2020: trends and developments. https://doi.org/10.2810/420678

144.

EMCDDA (2019) European drug report 2019: trends and developments. https://doi.org/10.2810/191370

145.

EMCDDA (2018) European drug report 2018: trends and developments. https://doi.org/10.2810/800331

146.

EMCDDA (2017) European drug report 2017: trends and developments. https://www.emcdda.europa.eu/publications/edr/trends-developments/2017_en. Accessed 4 Dec 2022

147.

EMCDDA (2016) European drug report 2016: trends and developments. https://www.emcdda.europa.eu/publications/edr/trends-developments/2016_en. Accessed 4 Dec 2022

148.

Reuter P, Pardo B (2017) New psychoactive substances: are there any good options for regulating new psychoactive substances? Int J Drug Policy 40:117–122. https://doi.org/10.1016/j.drugpo.2016.10.020 CrossRefPubMed

149.

Tavares LC (2004) QSAR: the Hansch’s approach. Quim Nova 27:631–639. https://doi.org/10.1590/s0100-40422004000400018 CrossRef

150.

Raies AB, Bajic VB (2016) In silico toxicology: computational methods for the prediction of chemical toxicity. Wiley Interdiscip Rev Comput Mol Sci 6:147–172. https://doi.org/10.1002/wcms.1240 CrossRefPubMedPubMedCentral

151.

Rodrigues CHP, Bruni AT (2019) In silico toxicity as a tool for harm reduction: a study of new psychoactive amphetamines and cathinones in the context of criminal science. Sci Justice 59:234–247. https://doi.org/10.1016/j.scijus.2018.11.006 CrossRefPubMed

Titel: Acute, chronic, and post-mortem toxicity: a review focused on three different classes of new psychoactive substances
verfasst von: Caio H. P. Rodrigues
Lívia S. Mariotto
Jade S. Castro
Paulo H. Peruquetti
Newton C. Silva-Junior
Aline T. Bruni
Publikationsdatum: 06.01.2023
Verlag: Springer Nature Singapore
Erschienen in: Forensic Toxicology / Ausgabe 2/2023
Print ISSN: 1860-8965
Elektronische ISSN: 1860-8973
DOI: https://doi.org/10.1007/s11419-022-00657-3

Neu im Fachgebiet Rechtsmedizin

16.08.2023 | Pathologie | CME

Springer Medizin

Acute, chronic, and post-mortem toxicity: a review focused on three different classes of new psychoactive substances

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Rechtsmedizin

Ovarialkarzinom: Molekularpathologie und molekular gesteuerte Therapie

Testung auf Mismatch-Reparatur-Defizienz und Mikrosatelliteninstabilität

Potential mechanisms of death in cases of fatal acid attacks

Rechtsmedizin im „forensischen Medienmarkt“

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2023

Cannabidiol in urine is not a proof of CBD consumption—lesson learned from urine sample analysis in routine caseworks

Detection of lisdexamfetamine and its metabolite d-amphetamine in urine and gastric contents collected from a cadaver at forensic autopsy

Urinary profiles of methoxyphenamine and its metabolite after inhalation of methoxyphenamine smoke in humans: aiming to distinguish between active and passive exposure

Analysis of degradation products of Novichok agents in human urine by hydrophilic interaction liquid chromatography–tandem mass spectrometry

Proteomic identification and quantification of Clostridium perfringens enterotoxin using a stable isotope-labelled peptide via liquid chromatography–tandem mass spectrometry

Identification of LSD analogs, 1cP-AL-LAD, 1cP-MIPLA, 1V-LSD and LSZ in sheet products

Neu im Fachgebiet Rechtsmedizin

Ovarialkarzinom: Molekularpathologie und molekular gesteuerte Therapie

Testung auf Mismatch-Reparatur-Defizienz und Mikrosatelliteninstabilität

Potential mechanisms of death in cases of fatal acid attacks

Rechtsmedizin im „forensischen Medienmarkt“